Highlights
- Second quarter net loss was USD 4,866,635 against USD 5,949,405 a year earlier.
- Cash and cash equivalents were USD 4,425,841 at June 30, 2026.
- The filing states there is substantial doubt about continuing as a going concern.
- Nasdaq notified the company on July 15, 2026 of a Market Value shortfall.
Actuate Therapeutics, Inc. (NASDAQ:ACTU) shares were trading near their all-time low at USD 0.3117 on November 6, 2026, down 4.68% on the day. The clinical stage biopharmaceutical company reported a second quarter net loss of USD 4,866,635 and cash and cash equivalents of USD 4,425,841 at June 30, 2026.
The company is developing elraglusib, a small molecule designed to enter cancer cells and block the enzyme glycogen synthase kinase-3 beta. It has not generated Revenue from product sales since its inception, according to its quarterly report.
Results for the Quarter and Six Months
Total operating expenses were USD 4,906,588 in the second quarter against USD 5,968,877 in the same quarter of 2025. Research and Development expense was USD 2,066,825 against USD 2,764,805, and general and administrative expense was USD 2,839,763 against USD 3,204,072.
The net loss was USD 4,866,635, or USD 0.20 per share, against USD 5,949,405, or USD 0.30 per share. For the six months ended June 30, 2026, the net loss was USD 10,492,384, or USD 0.44 per share, against USD 12,266,429, or USD 0.63 per share.
Research and development expense was USD 4,632,069 for the six months against USD 5,985,124. General and administrative expense was USD 5,980,475 against USD 6,349,337.
Balance Sheet and Going Concern Language
Total Assets were USD 5,199,339 at June 30, 2026, against USD 14,035,910 at December 31, 2025. Total liabilities were USD 4,210,187, and total stockholders' Equity was USD 989,152 against USD 7,924,003. The accumulated Deficit was USD 165,100,085.
Net cash used in Operating Activities was USD 9,422,450 for the six months against USD 8,792,501 a year earlier. The company reported Working Capital of USD 942,745.
The filing concludes that there is substantial doubt regarding the company's ability to continue as a going concern.
Financing Facilities
On November 28, 2025, the company entered into an At Market Issuance Sales Agreement with B. Riley Securities and Craig-Hallum Capital Group, allowing it to sell up to USD 100 million of common stock through an at-the-market program. The filing reports net proceeds of USD 1,249,591 under that facility.
The company also holds a committed equity Facility with B. Riley Principal Capital II, signed on March 27, 2025, covering up to USD 50 million of newly issued shares. It did not issue any shares under that facility during the six months ended June 30, 2026, and 3,364,407 shares of capacity remained.
Listing Status
The common stock is listed on the Nasdaq Global Market. On July 15, 2026, the company received a letter from Nasdaq stating that, for the 30-business day period ended July 14, 2026, it had not met the USD 50 million minimum market value of listed securities required for continued listing on that market.
The filing says the company intends to work to resolve the deficiency and regain compliance. It also notes that the shares could be moved to another Nasdaq tier if compliance is not regained.
Clinical and Regulatory Plans
The company said it plans to seek feedback from the U.S. Food and Drug Administration and the European Medicines Agency in 2026 on the design of clinical studies. These include a Phase 1/2 study in advanced cancer patients using an oral tablet formulation of elraglusib and a future study in metastatic pancreatic ductal adenocarcinoma.
The company develops elraglusib for high impact, difficult to treat cancers. Weighted average shares outstanding were 23,871,850 in the quarter, and 24,014,202 shares were outstanding on August 13, 2026.






Please wait processing your request...